Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30

NEXT STORY
BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting
PREV STORY
Résultats positifs de la plateforme ciblée en oncologie de Theratechnologies présentés en ligne à ASCO
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for initial treatment of metastatic non-squamous non-small cell lung cancer

Basel, 17 January 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that ...

author_avatar
NASDAQ Market News

XBiotech Announces Pricing of Public Offering of Common Shares

author_avatar
NASDAQ Market News

CMR Surgical expands into the Middle East

author_avatar
NASDAQ Market News